Publications

Antimicrobial Activity of Ceftaroline Tested against Staphylococcus aureus from Surgical Skin and Skin Structure Infections in USA Medical Centers, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Antimicrobial Activity of TD-1607 Tested against Contemporary (2010-2012) Methicillin-Resistant Staphylococcus aureus (MRSA) Strains, Lead author: Sader HS, presented at Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), Sept 6-9, 2014, Washington DC

Accuracy of Sensititre dry-form broth microdilution panels to determine ceftaroline-avibactam MIC values, Lead author: Jones RN, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Susceptibility testing of isolates displaying elevated colistin MIC values using polysorbate-80 (P-80), Lead author: Castanheira M, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Validation of a TREK diagnostic systems dry-form broth microdilution MIC product for testing ceftazidime-avibactam, Lead author: Jones RN, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Klebsiella pneumoniae belonging to ST258 from a New York city hospital carrying KPC-2- and VIM-4-encoding genes: Report from the SENTRY antimicrobial surveillance program, Lead author: Castanheira M, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Baseline activity of telavancin when tested against Gram-positive clinical isolates responsible for documented infections in USA hospitals (2011-2012) applying a revised susceptibility testing method, Lead author: Mendes RE, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Quality control ranges for performance assessment of a revised broth microdilution susceptibility testing method for telavancin, Lead author: Ross JE, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Revised reference broth microdilution method for testing telavancin: effect on MIC results and correlation with other testing methodologies, Lead author: Farrell DJ, presented at 114th annual American Society for Microbiology General Meeting (ASM), May 17 – 20, 2014, Boston, MA

Evaluation of EUCAST zone diameter breakpoints for Pseudomonas spp., Lead author: Ahman, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Global prevalence, genetics and clonal relatedness of macrolide resistance in Moraxella catarrhalis (2010-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

GSK2140944 MIC quality control ranges using a multi-laboratory study design, Lead author: Jones RN, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Azole resistance mechanisms found among fluconazole-resistant Candida albicans clinical isolates: Report from the SENTRY antifungal resistance programme, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against P. aeruginosa isolates from 15 European countries and Israel (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Carbapenem-resistant Klebsiella pneumoniae clinical isolate harbouring a blaIMP-4- and qnrS-carrying plasmid, as well as a conjugative blaKPC-2 plasmid, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from European hospitals: Results from the SENTRY Program (2010-2013), Lead author: Sader HS, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Characterization of intrinsic Beta-lactam resistance mechanisms among contemporary ceftazidime non-susceptible Pseudomonas aeruginosa from USA hospitals, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Linezolid susceptibility surveillance in Europe for 2013: ZAAPS Program (5,076 strains), Lead author: Jones RN, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Telavancin activity tested against Gram-positive clinical isolates from European hospitals (2011-2013) using a revised broth microdilution testing method: Redefining the baseline activity for telavancin, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of daptomycin and comparator agents tested against Methicillin-resistant S. aureus and vancomycin-resistant enterococci: Analysis of five-year trends in Europe and USA hospitals (2009-2013), Lead author: Sader HS, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae recovered principally from lower respiratory tract specimens in older adult patients (≥50 years of age) in select European countries (2009-2011), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

KPC-producing Pseudomonas aeruginosa from the United States: What is next?, Lead author: Castanheira M, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftolozane/tazobactam activity when tested against Gram-negative bacterial isolates from hospitalized patients with pneumonia in European hospitals (2011-2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Activity of oritavancin tested against Gram-positive clinical isolates responsible for documented skin and soft tissue infections in European hospitals (2011-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Polymyxin B: Can we create a better product?, Lead author: Kassamali, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftobiprole activity tested against bacterial isolates from hospitalized patients with pneumonia in European hospitals and Israel (2013), Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial Activity of Ceftobiprole Tested against Staphylococci and Streptococci from European Countries and Israel (2013), Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Current analysis of oritavancin potency when tested against vancomycin-resistant and -susceptible enterococcal clinical isolates recovered from European medical centres (2009-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Telavancin activity against uncommonly isolated Gram-positive pathogens responsible for documented infections in hospitals worldwide (2011-2013) when using a revised susceptibility testing method, Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Enterobacteriaceae isolates from 14 European countries and Israel (2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Ceftazidime-avibactam activity tested against select Gram-negative organisms from a global surveillance program (2011) in relation to the ceftazidime epidemiologic cut-off value, Lead author: Flamm R, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Antimicrobial activity of solithromycin tested against serotyped macrolide-resistant Streptococcus pneumoniae collected from medical centers across the USA (2012), Lead author: Farrell DJ, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Activity of oritavancin and comparator agents against multidrug-resistant staphylococcal and streptococcal isolates responsible for documented infections in European hospitals (2011-2013), Lead author: Mendes RE, presented at 24th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), May 10 – 13, 2014, Barcelona, Spain

Surveillance of antimicrobial resistance in contemporary clinical isolates of Bordetella pertussis in Ontario, Canada. by Marchand-Austin A, Memari N, Patel SN, Tang P, Deeks SL, Jamieson FB, Crowcroft NS and Farrell DJ published in Int. J. Antimicrob. Agents. 2014; 44 (1): 82-84

Antimicrobial susceptibility of clinical isolates of anaerobic bacteria in Ontario, 2010-2011. by Marchand-Austin A, Rawte P, Toye B, Jamieson FB, Farrell DJ and Patel SN published in Anaerobe. 2014; 28: 120-125

Antimicrobial susceptibility of gram-negative organisms isolated from patients hospitalized in intensive care units in United States and European hospitals (2009-2011). by Sader HS, Farrell DJ, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 443-448

Antimicrobial activity of ceftaroline tested against drug resistant subsets of Streptococcus pneumoniae from United States medical centers. by Flamm RK, Sader HS, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (4): 2468-2471

Antimicrobial activity of ceftaroline combined with avibactam tested against bacterial organisms isolated from acute bacterial skin and skin structure infections in United States medical centers (2010-2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 449-456

Ceftazidime/avibactam activity tested against Gram-negative bacteria isolated from bloodstream, pneumonia, intra-abdominal, and urinary tract infections in United States medical centers (2012). by Flamm RK, Farrell DJ, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2014; 69 (6): 1589-1598

Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010. by Farrell DJ, Flamm RK, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (7): 3882-3888

Activity of ceftaroline-avibactam tested against contemporary Enterobacteriaceae isolates carrying ß-lactamases prevalent in the United States. by Castanheira M, Williams G, Jones RN and Sader HS published in Microb. Drug Res. 2014; 20 (5): 436-440

Activity of echinocandins and triazoles against a contemporary (2012) worldwide collection of yeast and moulds collected from invasive infections. by Castanheira M, Messer SA, Jones RN, Farrell DJ and Pfaller MA published in Int. J. Antimicrob. Agents. 2014; 44 (4): 320-326

Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: An epidemiological and structural perspective. by Alm RA, McLaughlin RE, Kos VN, Sader HS, Iaconis JP and Lahiri SD published in J. Antimicrob. Chemother. 2014; 69 (8): 2065-2075

In vitro activity of ceftaroline tested against isolates from the Asia-Pacific region and South Africa (2011). by Flamm RK, Jones RN and Sader HS published in J. Global Antimicrob. Res. 2014; 2 (2): 183-189

Revised reference broth microdilution method for testing telavancin: Effect on MIC results and correlation with other testing methodologies. by Farrell DJ, Mendes RE, Rhomberg PR and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (9): 5547-5551

Ceftaroline activity tested against contemporary Latin American bacterial pathogens (2011). by Flamm RK, Sader HS and Jones RN published in Braz. J. Infect. Dis. 2014; 18 (2): 187-195

Oritavancin activity against Staphylococcus aureus causing invasive infections in USA and European hospitals. A five-year international surveillance program. by Mendes RE, Sader HS, Flamm RK, Farrell DJ and Jones RN published in Antimicrob. Agents Chemother. 2014; 58 (5): 2921-2924

Ceftaroline activity tested against bacterial isolates from pediatric patients: Results from the Assessing Worldwide Antimicrobial Resistance and Evaluation program for the United States (2011-2012). by Sader HS, Mendes RE, Farrell DJ, Flamm RK and Jones RN published in Pediatr. Infect. Dis. J. 2014; 33 (8): 837-842

Ceftaroline activity against organisms isolated from respiratory tract infections in USA hospitals: Results from the AWARE Program, 2009-2011. by Flamm RK, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2014; 78 (4): 437-442

Ceftaroline activity tested against uncommonly isolated gram-positive pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2008- 2011). by Sader HS, Jones RN, Stilwell MG and Flamm RK published in Int. J. Antimicrob. Agents. 2014; 43 (3): 284-286